Clinical efficacy of endoscopic dilation combined with bleomycin injection for benign anastomotic stricture after rectal surgery

Xin Miao, MDa, Li Liu, PhDb, Xiang Wang, MDb, Zhining Fan, PhDb, Lin Miao, PhDc, Jiankun Wang, MDd,∗

Abstract

Benign anastomotic stricture is a frequent complication after rectal surgery. This study investigated the feasibility of endoscopic dilation combined with bleomycin injection for benign anastomotic stricture after rectal surgery. 31 patients who diagnosed with benign anastomotic stricture after rectal surgery were included in this study. 15 patients received simple endoscopic dilation (dilation group) and 16 patients received endoscopic dilation combined with bleomycin injection (bleomycin group). The clinical effect and adverse events were compared in the 2 groups. The strictures were managed successfully and the obstruction symptoms were relieved immediately. There were 2 minor complications in dilation group and 3 minor complications in bleomycin group. The difference was not significant between the 2 groups (P > .05). During the follow-up, the mean reintervention interval was 4.97 ± 1.00 months in dilation group and 7.60 ± 1.36 months in bleomycin group. The median treatment times was 4 (range 3–5) in dilation group and 2 (range 2–3) in bleomycin group. The differences in the 2 groups were significant (P < .05). Compared with endoscopic dilation, endoscopic dilation combined with bleomycin injection may reduce the treatment times and prolong the reintervention interval, which is a safe and effective endoscopic management for benign anastomotic stricture after rectal surgery.

Abbreviations: cm = centimeter, mins = minutes, mg = milligram, ml = milliliter, mm = millimeter, SD = standard deviation.

Keywords: benign anastomotic stricture, bleomycin, endoscopic dilation, rectal surgery

1. Introduction

Benign anastomotic stricture is one of the common complications after colorectal surgery. Low-set anastomoses, mechanical anastomosis, and other factors can promote anastomotic stricture. Influenced by these risk factors, the incidence of benign anastomotic stricture is from 5 to 30%.1,2 The main clinical features include dyschezia, abdominal pain, and even ileus. Patients suffer from them. At present, the effective treatments are surgery and endoscopic management. Even though the effect of surgery is remarkable, it may lead to large injury, high cost, and restenosis. Therefore, surgery is usually used for complex situations. The most common endoscopic management is dilation. After 1–3 dilations, many patients can achieve cure. But some patients are difficult to be treated, even with repeated treatment.3 Auxiliary ways of endoscopic dilation have been applied for improving the effect, such as steroid or mitomycin injection. Due to the limited sample size and research type, their roles remain uncertain.

Bleomycin is a common chemotherapy drug, which is used for malignant tumors. Besides, efficacy of bleomycin for healing pterygium and hyperplastic scar have been confirmed.4–6 There are no studies to research the usefulness of bleomycin in gastrointestinal benign anastomotic stricture.

Therefore, a feasibility study was made to compare simple endoscopic dilation with endoscopic dilation combined with bleomycin injection. The clinical effect and adverse events were recorded.

2. Materials and Methods

2.1. Patients

Patients from Jiangsu Province Hospital, the Second Affiliated Hospital of Nanjing Medical University and Taizhou Traditional Medical Hospital between April 2014 and April 2019 were strictly selected according to standards. All patients underwent anterior resection for rectal cancer. This research followed the principles of the Declaration of Helsinki. Inclusion criteria were as follows: (1) difficulty with bowel movements, constipation or abdominal distension after anus-retained rectal operation. (2) Colonoscope couldn’t pass through the anastomotic...
the anastomotic stricture was proved benign with routine biopsies. Exclusion criteria were as follows: (1) anastomotic abscess or fistula, (2) drug allergy or a low white blood cell count, (3) severe comorbidities, such as coagulation disorders, cardiopulmonary dysfunction. We explained the advantages and disadvantages of the 2 endoscopic treatments. Patients could choose their respective therapy on an as-needed basis. Endoscopic dilation combined with bleomycin injection was not suggested if patients had the drug allergy or a low white blood cell count. This study was approved by the Ethics Committee of Jiangsu Province Hospital (2018-SR-258). Before the treatment, written informed consents were obtained from all patients.

2.2. Operation procedure

After preoperative examinations, colonoscopy was performed by skilled doctors to detect the stricture site. Patients were under conscious sedation. Before treatment, the diameter of the anastomotic site was recorded with a biopsy forcep (MTN-BF-23, Micro-Tech, Nanjing, China). The forcep was 6 millimeter (mm) in width when it was opened. Then a balloon (CRE Wireguided Balloon Dilator, Boston Scientific, Minneapolis, USA) was inserted for dilation in all patients. The diameter of the balloon was 16–20 mm. The dilation was repeated 3 times. Every time the procedure was held for 3 minutes (mins). Then 10 milliliter (ml) bleomycin (10 milligram (mg) of 1 mg/ml, Haizheng, Zhejiang, China) was injected into the anastomotic site (at the 3, 6, 9, and 12 o’clock positions) with an injection needle (INJ1-A1, Medwork GmbH, Höchstadt, Germany) in bleomycin group (shown in Fig. 1). Finally, the diameter of the anastomotic site was recorded again with the balloon.

2.3. Postoperative care and follow-up

After operation, all patients were fasted for 24 hours. If there were no related complications such as fever, abdominal pain or bloody stools, liquid diet was permitted to take. Patients were discharged when the obstruction symptoms disappeared. All patients were followed up at the outpatient department. The least follow-up period was 2 years. Patients who had obstruction symptoms recurred were admitted to the hospital and received the same endoscopic treatment again.

2.4. Statistical analysis

Statistical analyses were performed using SPSS 19.0 software (IBM, Armonk, NY, USA). Quantitative variables were expressed as mean ± standard deviation (SD) in normal distribution and median (range) in abnormal distribution. Qualitative variables were described as frequency or percentage. Student t or analysis of variance (ANOVA) was used to compare continuous variables. Chi-squared or Fisher exact test was used to compare categorical variables. Difference between the 2 groups was considered statistically significant when the P value was <0.05.

3. Results

A total of 31 patients with rectal benign anastomotic stricture were enrolled in this research, with 15 patients (10 men and 5 women) in the dilation group and 16 patients (9 men and 7 women) in the bleomycin group. All patients had history of rectal cancer operation and the lower digestive tract was rebuilt with end- to- end anastomose. The chosen patients should satisfy all inclusion criteria and eliminate every exclusion

![Figure 1. Endoscopic dilation combined with bleomycin injection. (a) The anastomotic stricture after rectal surgery. (b) Endoscopic dilation. (c) The anastomotic site after dilation. (d) Endoscopic bleomycin injection after dilation. (e) The anastomotic site after 1 month.](image)
Follow-up period, months, mean ± SD 26.90 ± 1.70 27.21 ± 1.85 0.63

Minor complication 2 3

Major complication 0 (0) 0 (0)

The kind of anastomosis Manual anastomosis 3 2 Mechanical anastomosis (stapler) 12 14

Distance to anus, cm, mean ± SD 6.33 ± 2.47 5.88 ± 2.55 0.62

Male/femal, n 10/5 9/7 0.72

Anastomotic diameters before operation, cm, mean ± SD 0.47 ± 0.14 0.52 ± 0.18 0.38

The kind of anastomosis

Mechanical anastomosis (stapler) 12 14

Manual anastomosis 3 2

SD = standard deviation.

4. Discussion

Anastomotic stricture is one of the common complications after colorectal surgery, which includes benign stricture and malignant stricture. The latter is usually caused by tumor relapse. The benign anastomotic stricture occurs more commonly in rectal surgery than colonic surgery because of the anastomosis method, and it has a deleterious influence on patients’ life quality. The main cause of benign anastomotic stricture is hyperplastic scar.[10] The main therapy for benign anastomotic stricture is endoscopic dilation. While some patients respond poorly to it. Repeated dilation may lead to mucosa injury and increase the incidence of perforation. Therefore, extending no-structre period and reducing treatment times is quite essential. Endoscopic stent implantation is a solution for refractory anastomotic stricture, especially for acute obstruction. It can relieve the symptoms rapidly. But the long-term effect of stent implantation is uncertain, which is influenced by stent migration and restenosis.[11, 12] Endoscopic incision was initially used for esophageal rings,[13] then it has been used to treat refractory digestive tract stricture.[14] This technology is still difficult and most primary hospitals can’t carry out the operation now. In 1970s, local injection with corticosteroid was first reported to relieve gastrointestinal stricture.[15] Researchers hoped the treatment times and the recurrence rate could be decreased by endoscopic dilation combined with corticosteroid injection. However, the results are still controversial. Some studies indicated endoscopic dilation combined with corticosteroid injection might prolong symptom-free period and decrease the dilation frequency.[16, 17] While Hirdes et al revealed corticosteroid injection combined with dilation didn’t prolong patency period in patients with anastomotic stricture.[18] Therefore, further studies are needed. Bleomycin can inhibit the transforming growth factor expression, prohibit the fibroblast proliferation and reduce the collagen generation. Excessive fibroblast proliferation and collagen generation lead to postoperative scar formation. Therefore, bleomycin has the antistenosis effect in theory.[19] As the analogue of bleomycin, mitomycin has been proved the value for treating benign esophageal stricture.[19, 20] However, the efficacy of mitomycin for rectal anastomotic stricture was not satisfactory in our preliminary study, especially for refractory stricture.

Our study compared the efficacy of combination therapy with simple endoscopic dilation preliminarily. No matter in bleomycin group or dilation group, most patients develop anastomotic stricture after receiving mechanical anastomosis with staplers. It has been found that mechanical anastomoses are associated with higher levels of collagen deposition and more inflammation, which may lead to stricture formation.[21] Besides, surgeons can control the caliber and shape of anastomoses better when they are using the hand-sewn method.[22] The bleomycin group had the longer reintervention interval and less treatment times than dilation group. It indicated the clinical effect of combination therapy was better for benign anastomotic stricture after rectal surgery. It is possible that endoscopic dilation only tear scar tissue simply. The surrounding scar tissue will develop restenosis after a while. Bleomycin can effectively inhibit the formation of restenosis by its pharmacological role.[23] What is more, endoscopic dilation combined with bleomycin injection did not cause any severe adverse events. Only 2 patients had low grade fever and 1 patient had hematochezia. The incidence of complications in bleomycin group was similar to that in dilation group, which might be caused by endoscopic dilation itself. During the follow-up, no other complications were observed. Local bleomycin injections didn’t cause mucosa injury and systemic side effects. These results were listed in Table 2.
In conclusion, endoscopic dilation combined with bleomycin injection is confirmed to be an effective and safe method for benign anastomotic stricture after rectal surgery. Compared with simple dilation, endoscopic dilation combined with bleomycin injection can prolong anastomosis patency period and reduce treatment times, which is especially applicable to refractory anastomotic stricture. Although the study has a small sample and short-term follow-up. Large-scale, randomized controlled trials and long-term follow-up evaluation are needed in the future. Nevertheless, the promising results of our study may open new opportunities for endoscopic treatment of anastomotic stricture.

Author contributions
Conceptualization: Jiankun Wang.
Data curation: Jiankun Wang.
Formal analysis: Li Liu.
Investigation: Xin Miao.
Methodology: Xin Miao, Xiang Wang.
Project administration: Xin Miao, Zhining Fan, Lin Miao, Jiankun Wang.
Resources: Xin Miao.
Software: Xin Miao.
Validation: Xin Miao.
Writing – original draft: Xin Miao, Li Liu, Xiang Wang.
Writing – review & editing: Zhining Fan, Lin Miao, Jiankun Wang.

References
[1] Luchtefeld MA, Milsom JW, Senagore A, et al. Colorectal anastomotic stenosis. Results of a survey of the ASCRS membership. Dis Colon Rectum. 1989;32:733–6.
[2] Polese L, Vecchiato M, Frigo AC, et al. Risk factors for colorectal anastomotic stenosis and their impact on quality of life: what are the lessons to learn. Colorectal Dis. 2012;14:e124–8.
[3] Kwon YH, Jeon SW, Lee YK. Endoscopic management of refractory benign colorectal strictures. Clin Endosc. 2013;46:472–5.
[4] Lee Da, Lee TC, Cortes AE, et al. Effects of mithramycin, mitomycin, daunorubicin, and bleomycin on human subconjunctival fibroblast attachment and proliferation. Invest Ophthalmol Vis Sci. 1990;31:2136–44.
[5] Payavipapong K, Niumpradit N, Priyayanand C, et al. The treatment of keloids and hypertrophic scars with intralesional bleomycin in skin of color. J Cosmet Dermatol. 2015;14:83–90.
[6] Ledon JA, Savas J, Franca K, et al. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg. 2015;39:1743–57.
[7] Wang J, Zhao L, Wu R, et al. Appropriate duration of endoscopic dilation for postoperative benign esophageal strictures. Surg Endosc. 2022;36:1263–8.
[8] Chan RH, Lin SC, Chen PC, et al. Management of colorectal anastomotic stricture with multidiameter balloon dilation: long-term results. Tech Coloproctol. 2020;24:1271–6.
[9] Gusmon-Oliveira CC, Kuboki YM, de Paulo GA, et al. Endoscopic injection of mitomycin C for the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients treated for head and neck cancer. Gastroenterol Res Pract. 2018;5428157.
[10] Davis B, Rivadeneira DE. Complications of colorectal anastomoses: leaks, strictures, and bleeding. Surg Clin North Am. 2013;93:61–87.
[11] Caruso A, Conigliaro R, Manta R, et al. Fully covered self-expanding metal stents for refractory anastomotic colorectal strictures. Surg Endosc. 2015;29:1175–8.
[12] Repici A, Pagano N, Rando G, et al. A retrospective analysis of early and late outcome of biodegradable stent placement in the management of refractory anastomotic colorectal strictures. Surg Endosc. 2013;27:2487–91.
[13] Ravich WJ. Endoscopic Management of Benign Esophageal Strictures. Curr Gastroenterol Rep. 2017;19:50.
[14] Bravi I, Ravizza D, Fiori G, et al. Endoscopic electrocautery dilation of benign anastomotic colonic strictures: a single-center experience. Surg Endosc. 2016;30:229–32.
[15] Mendelsohn HJ, Maloney WH. The treatment of benign strictures of the esophagus with cortisone injection. Ann Otol Rhinol Laryngol. 1970;79:900–4.
[16] Pereira-Lima JC, Lemos Bonotto M, Hahn GD, et al. A prospective randomized trial of intralesional triamcinolone injections after endoscopic dilation for complex esophagogastric anastomotic strictures: steroid injection after endoscopic dilation. Surg Endosc. 2015;29:1156–60.
[17] Orive-Calzada A, Bernal-Martinez A, Navajas-Laboa M, et al. Efficacy of intralesional corticosteroid injection in endoscopic treatment of esophageal strictures. Surg Laparosc Endosc Percutan Tech. 2012;22:518–22.
[18] Hirdes MM, van Hoot JE, Koornstra JJ, et al. Endoscopic corticosteroid injections do not reduce dysphagia after endoscopic dilation therapy in patients with benign esophagogastric anastomotic strictures. Clin Gastroenterol Hepatol. 2013;11:795–801.e1.
[19] Hirdes MM, van Hoot JE, Koornstra JJ, et al. Locoregional mitomycin C injection for esophageal strictures after endoscopic submucosal dissection, Endoscopy, 2012;44:622–5.
[20] Zhang Y, Wang X, Liu L, et al. Intramuscular injection of mitomycin C combined with endoscopic dilation for benign esophageal strictures. J Dig Dis. 2015;16:370–6.
[21] Reif de Paula T, Simon H, Shah M, et al. Analysis of the impact of EEA stapler size on risk of anastomotic complications in colorectal anastomosis: does size matter? Tech Coloproctol. 2020;24:283–90.
[22] Bressan A, Marinii L, Michelotto M, et al. Risk factors including the presence of inflammation at the resection margins for colorectal anastomotic stenosis following surgery for diverticular disease. Colorectal Dis. 2018;20:923–30.